EP Patent
EP2590620B1 — Stable aqueous formulations comprising poorly water soluble active ingredients
Assigned to KRKA dd · Expires 2020-01-22 · 6y expired
What this patent protects
Patent listed against Xeglyze.
Drugs covered by this patent
- Xeglyze (ABAMETAPIR) · Hatchtech
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.